Université Bordeaux, INSERM U1026, Bioingénierie tissulaire, F-33000 Bordeaux, France. CHU de Bordeaux, Pôle Odontologie et Santé Buccale, F-33000 Bordeaux, France.
Biomed Mater. 2017 Oct 3;12(6):065003. doi: 10.1088/1748-605X/aa78d0.
Vascular grafts made of synthetic polymers perform poorly in small-diameter applications (cardiac and peripheral bypass). Chitosan is a biocompatible natural polymer that can provide a novel biological scaffold for tissue engineering development. The goal of this study was to demonstrate the biocompatibility of a novel chitosan preparation in vitro and in vivo, and to assess its potential as a scaffold for vascular applications.
A series of experiments of increasing complexity, ranging from in vitro biocompatibility and hemocompatibility tests to in vivo studies in small and large animals (rats and sheep), was performed to provide a comprehensive analysis of chitosan hydrogels' biological properties. In vitro studies established that: (i) chitosan supported human endothelial progenitor cells adhesion, proliferation and resistance to physiological shear stress; (ii) chitosan did not activate platelets, the complement system, or the intrinsic coagulation pathway. In vivo results showed: (iii) no resorption of chitosan and no chronic inflammation at 60 days in a rat heterotopic implantation model (magnetic resonance imaging and histology); (iv) no flow obstruction (Doppler ultrasound) and no thrombus formation (histology and scanning electron microscopy) at 2 h after a carotid arteriotomy repair with chitosan patches in sheep. Finally, two chitosan tubes were implanted as carotid interposition grafts for 3 days in sheep showing that chitosan was strong enough to be sutured, to withstand arterial pressure, and no flow obstruction was observed through this short period.
Chitosan-based hydrogels displayed promising in vitro biocompatibility and hemocompatibility properties as well as in vivo short-term performance.
由合成聚合物制成的血管移植物在小直径应用(心脏和外周旁路)中表现不佳。壳聚糖是一种生物相容性的天然聚合物,可为组织工程开发提供新型生物支架。本研究的目的是证明新型壳聚糖制剂的体外和体内生物相容性,并评估其作为血管应用支架的潜力。
进行了一系列越来越复杂的实验,从体外生物相容性和血液相容性测试到小型和大型动物(大鼠和绵羊)的体内研究,以全面分析壳聚糖水凝胶的生物学特性。体外研究表明:(i)壳聚糖支持人内皮祖细胞的黏附、增殖和抵抗生理剪切力;(ii)壳聚糖不会激活血小板、补体系统或内在凝血途径。体内结果表明:(iii)在大鼠异位植入模型中 60 天无壳聚糖吸收和慢性炎症(磁共振成像和组织学);(iv)在绵羊颈动脉切开修复中使用壳聚糖补片 2 小时后无血流阻塞(多普勒超声)和无血栓形成(组织学和扫描电子显微镜)。最后,两个壳聚糖管被植入绵羊作为颈动脉间置移植物 3 天,表明壳聚糖足够坚固,可以缝合,能够承受动脉压,并且在这段短时间内没有观察到血流阻塞。
基于壳聚糖的水凝胶表现出有前途的体外生物相容性和血液相容性特性以及体内短期性能。